Most Popular

Roth Capital Reiterates Buy On Alcobra Following The Completion Of Phase III Clinical Trial of MDX

In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a price target of $40.00, …

NPS Pharma: Rems Concern? Overblown, Says Canaccord

In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of NPS Pharma (NASDAQ:NPSP) with a $42 price target, following concerns …

Cantor Raises Yahoo! Price Target To $43 On The Heels Of Alibaba’s IPO

In a report published today, Cantor Fitzergald analyst Youssef Squali maintained a Buy rating on Yahoo! (NASDAQ:YHOO) and raised his price target to …

Ahead Of Alibaba’s IPO: Cantor Initiates Buy, Sets $90 Price Target

In a special research report released today, Cantor Fitzgerald analyst Youssef Squali initiated a Buy rating on Alibaba Group (NYSE:BABA) with a $90 price target, ahead …

Brean Capital Maintains Bullish Stance On Repros, $41 PT

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target …

CTI BioPharma: Partnership For Pixuvri Highlights Potential, Says H.C. Wainwright

In a research report issued today, H.C.

Catalyst: Roth Capital Expects Positive Results From Phase 3 Study Of Firdapse

In a research report issued today, Roth Capital analyst Scott Henry assigned a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $5.00 price …

H.C. Wainwright Remains Bullish On Keryx Following Ferric Citrate FDA Approval

In a research report issued today, H.C.

Brean Capital Reiterates Buy On NPS Pharmaceuticals On The Back Of FDA Panel Outcome

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a $41 price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts